Please login to the form below

Not currently logged in
Email:
Password:

FDA asks for more data on Merck & Co's Zetia combo

While allergy immunotherapy clears phase III trial

The US FDA says it needs additional data before it can approve Merck & Co's new cholesterol-lowering drug MK-0653c, which combines its Zetia (ezetimibe) drug with generic atorvastatin.

The marketing application looks set to be delayed by a year or more as the agency has requested an additional clinical trial of the combination product. Meanwhile, a lawsuit filed by Pfizer, which sells the original Lipitor brand of atorvastatin, could delay a launch for even longer.

MK-0653c represents an attempt by Merck to inject some new momentum into its flagging ezetimibe franchise, which after a buoyant start has seen sales slide.

Merck said it plans to discuss next steps with the agency in the near future, including new data that are expected to be available later this year, which the company believes may address the FDA's comments.

Last year, Zetia saw its sales growth flatten to 2 per cent, bringing in $2.4bn in revenues, while Vytorin, a combination of ezetimibe with older statin drug simvastatin, shrank 7 per cent to $1.88bn.

Merck has been hoping that the inclusion of top-selling atorvastatin in MK-0653c would create a more powerful cholesterol-lowering drug and help patients with high cholesterol achieve greater reductions.

Analysts have suggested that MK-0653c could add another $500m to the franchise within three years of launch.


Allergy immunotherapy clears phase III trial

Meanwhile, there was better news for Merck after a phase III trial of its allergy immunotherapy tablet (AIT) for ragweed pollen allergy generated positive results, setting up a regulation submission in 2013.

The study results showed that the use of ragweed AIT significantly reduced a combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in ragweed-allergic adults with or without asthma.

Merck is also developing an AIT against grass pollen allergy which could also be filed in 2013. The company licenses US, Canadian and Mexican rights to the AITs from Denmark-based ALK Abello.

6th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics